|
WO2021079958A1
|
|
Combination of anti-garp antibody and immunoregulator
|
|
WO2021075538A1
|
|
Method for producing bicyclic phosphoramidite
|
|
WO2021049504A1
|
|
Galnac-oligonucleotide conjugate for liver-targeted delivery use, and method for producing same
|
|
WO2021025148A1
|
|
Therapeutic agent for cancer having resistance to anti-ccr4 antibody
|
|
WO2021010301A1
|
|
ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
|
|
WO2020246488A1
|
|
COMPOUND STABILIZING COMPLEX CONTAINING NuMA1 AND CKAP5
|
|
WO2020246487A1
|
|
Compounds having dispiro diketopiperazine structure
|
|
WO2020240467A1
|
|
Dosage of an antibody-drug conjugate
|
|
WO2020196712A1
|
|
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
|
TW202102228A
|
|
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
WO2020196475A1
|
|
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
WO2020179859A1
|
|
Pyrrolopyrazole derivative
|
|
TW202045491A
|
|
Azole derivatives
|
|
TW202045527A
|
|
Methods for purifying antibodies comprising of a process by using activated carbon materials
|
|
TW202043240A
|
|
Amino acid compound
|
|
TW202045515A
|
|
Ester compound
|
|
TW202045506A
|
|
Pyrazole compound
|
|
TW202043239A
|
|
Substituent-including urea compound
|
|
WO2020138011A1
|
|
Terephthalic acid derivative having ring-fused structure
|
|
WO2020130125A1
|
|
Combination of antibody-drug conjugate and kinase inhibitor
|
